Compare Crowdstrike Holdings Inc (CRWD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs BIO-TECHNE Corp — how do they compare? Crowdstrike Holdings Inc trades at $266.7 (market cap $271.79B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Crowdstrike Holdings Inc is far larger — about 23.9× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crowdstrike Holdings Inc for 97 Days and BIO-TECHNE Corp for 63 Days on average.
| CRWD | TECH | |
|---|---|---|
Market Cap | $271.79B | $11.37B |
Volume | 8,767,597 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $278.86 | $72.61 |
52-Week Low | $87.56 | $43.31 |
Typical Hold Time | 97 Days | 63 Days |
Enterprise Value | $267.60B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $265.44, down 4.81% today but remains near its 52-week high. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings expectations. Revenue growth remains robust at $3.95 billion for 2025, though profitability is challenged with a net loss of $19.27 million. Analyst sentiment is overwhelmingly positive with 76% buy ratings and a $235.74 consensus price target, while recent news highlights AI-driven cybersecurity opportunities.
CrowdStrike presents a growth-focused opportunity with strong revenue expansion and market leadership in AI-native cybersecurity. However, elevated valuation multiples and inconsistent profitability create risk. The stock's proximity to all-time highs suggests near-term consolidation potential, but long-term prospects remain favorable given cybersecurity demand trends and AI integration.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
